Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies (2022)
- Authors:
- USP affiliated authors: ANDRICOPULO, ADRIANO DEFINI - IFSC ; FERREIRA, LEONARDO LUIZ GOMES - IFSC
- Unidade: IFSC
- DOI: 10.1039/D2MD00262K
- Subjects: DOENÇA DE ALZHEIMER; COMPOSTOS HETEROCÍCLICOS; FARMACOCINÉTICA
- Language: Inglês
- Imprenta:
- Source:
- Título: RSC Medicinal Chemistry
- ISSN: 2632-8682
- Volume/Número/Paginação/Ano: v. 13, n. 12, p. 1644-1656 + supplementary information, Dec. 2022
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
MACHADO, Valkiria et al. Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies. RSC Medicinal Chemistry, v. 13, n. 12, p. 1644-1656 + supplementary information, 2022Tradução . . Disponível em: https://doi.org/10.1039/D2MD00262K. Acesso em: 01 abr. 2026. -
APA
Machado, V., Cenci, A. R., Teixeira, K. F., Sens, L., Tizziani, T., Nunes, R. J., et al. (2022). Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies. RSC Medicinal Chemistry, 13( 12), 1644-1656 + supplementary information. doi:10.1039/D2MD00262K -
NLM
Machado V, Cenci AR, Teixeira KF, Sens L, Tizziani T, Nunes RJ, Ferreira LLG, Yunes RA, Sandjo LP, Andricopulo AD, Oliveira AS. Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies [Internet]. RSC Medicinal Chemistry. 2022 ; 13( 12): 1644-1656 + supplementary information.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1039/D2MD00262K -
Vancouver
Machado V, Cenci AR, Teixeira KF, Sens L, Tizziani T, Nunes RJ, Ferreira LLG, Yunes RA, Sandjo LP, Andricopulo AD, Oliveira AS. Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies [Internet]. RSC Medicinal Chemistry. 2022 ; 13( 12): 1644-1656 + supplementary information.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1039/D2MD00262K - Novel brominated vinylic fatty acids effectively inhibit the leishmania topoisomerase IB enzyme mediated by halogen bond formation
- 3D QSAR studies for a series of Trypanosoma cruzi dehydrogenase inhibitors
- COVID-19: small-molecule clinical trials landscape [Editorial]
- Cancer estimates in Brazil reveal progress for the most lethal malignancies [Editorial]
- In vitro leishmanicidal activity of novel N-arylspermidine derivatives
- Chemoinformatics approaches to structure- and ligand-based drug design
- Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial]
- World chagas disease day and the new road map for neglected tropical diseases. [Editorial]
- Experimental and computational investigations on a series of drug candidates for Chagas disease
- Design, synthesis, and biological evaluation of aryldiazepane derivatives against Trypanosoma cruzi
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
